---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-163895"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T03:49:22.798191+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences reaffirms $89-94M 2023 revenue guidance; Palmetto proposes LCD deeming OMNI investigational

## Summary
- Reaffirmed FY 2023 revenue guidance of $89-94M (25-32% YoY growth) and average quarterly adjusted opex of ~$30.5M.
- Palmetto GBA published proposed LCD on June 8 classifying non-implantable MIGS (including OMNI) as investigational; open meeting July 17.
- Palmetto and WPS (proposed LCD June 1) states accounted for ~23% of 2022 Surgical Glaucoma revenue.
- NGS plans to publish proposed LCD on June 22 with open meeting July 13; five MACs covering 63% of revenue have discussed.
- Company says even if LCDs are finalized, no material impact on 2023 revenue due to 180-day implementation period.

## SEC filing metadata
- accession: 0001193125-23-163895
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312523163895/0001193125-23-163895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312523163895/d449969d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-163895
- JSON: https://secwatch.observer/filing/0001193125-23-163895.json
- Plain text: https://secwatch.observer/filing/0001193125-23-163895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.